Studies on the processing of herbal medicines (III) - HPLC analysis of magnolol and inhibitory effects on the formation of advanced glycation endproducts(AGEs) in vitro of unprocessed- and processed Magnolia Bark

Korean Journal of Pharmacognosy

Volumn 33, Issue 4, 2002, Pages 308-311

  Kim, Jin Sook ^a   Kim, Hyeun Jeong ^a   Ko, Jin Hee ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Advanced glycation endproduct(AGEs); Diabetic nephropathy; Magnolia Bark; Magnolol; Processing

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HERBACEOUS AGENT; MAGNOLOL;

ANTIOXIDANT ACTIVITY; ARTICLE; BARK; DRUG FORMULATION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; PHYTOCHEMISTRY;

EID: 0036947794     PISSN: 02533073     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Park, Y., Lee, H., Koh, C.S., Min, H., Yoo, K., Kim, Y. and Shin, Y. (1995) Prevalence of diabetes and IGT in Yonchon County, South, Korea. Diabetes care 18: 545-548.
2. Nakagawa, T., Yokozawa, T. and Terasawa, K. (2001) A study of Kampo medicines in a diabetic nephrophathy model. J. of Trad. Med. 18: 161-168.
3. Yokozawa, T., Nakagawa, T. and Terasawa, K. (2001) Effects of oriental medicines on the production of advanced glycation products. J. of Trad. Med. 18: 107-112.
4. Vinson, J.A. and Howard, T.B. III (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. Nutritional Biochemistry 7: 659-663.
5. Smith, P.R. and Thornalley, P.J. (1992) Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Eur. J. Biochem. 210: 729-739.
6. Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li. Y.M. and Steffs, M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. 89: 2873-2877.
7. Edelstein, D. and Brownlee, M. (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41: 26-29.
8. Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. and Cerami, A. (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Sciences 232: 1629-1632.
9. Shin, T.Y., Kim, D.K., Chae, B.S. and Lee, E.J. (2001) Antiallergic action of Magnolia officinalis on immediate hypersensitivity reaction. Arch. Pharm. Res. 24: 249-255.
10. Ikarashi, Y., Yuzurihara, M., Sakakibara, I., Nakai, Y., Hattori, N. and Maruyama, Y. (2001) Effects of extract of the bark of Magnolia obovata and its biphenolic constituents magnolol and honokiol on histamine release from peritoneal mast cells in rats. Planta Med. 67: 709-713.
11. Park, H.J., Kwon, S.H., Han, Y.N., Choi, J.W., Miyamoto, K., Lee, S.H. and Lee, K.T. (2001) Apoptosis-inducing costunolide and a novel acyclic monoterpene from the stem bark of Magnolia sieboldii. Arch. Pharm. Res. 24: 342-348.
12. Son, H.J., Lee, H.J., Yun-Choi, H.S. and Ryu, J.H. (2000) Inhibitors of nitric oxide synthesis and TNF-alpha expression from Magnolia obovata in activated macrophages. Planta Med. 66: 467-471.
13. Bang, K.H., Kim, Y.K., Min, B.S., Na M.K., Rhee, Y.H., Lee, J.P. and Bae, K.H. (2000) Antifungal activity of magnolol and honokiol. Arch. Pharm. Res. 23: 46-49.
14. Kuribara, H., Stavinoha, W..B. and Maruyama, Y. (1999) Honokiol, a putative anxiolytic agent extracted from magnolia bark, has no diazepam-like side-effects in mice. J Pharm. Pharmacol. 51: 97-103.
15. Konoshima, T., Kozuka, M., Tokuda, H., Nishino, H., Iwashima, A., Haruna, M., Ito, K. and Tanabe, M. (1991) Studies on inhibitors of skin tumor promotion, IX Neolignans from Magnolia officinalis. J. Nat. Prod., 54: 816-822.